Press release

Soho Flordis International signs an agreement for the acquisition of Potters and the Equazen™ brand portfolio from Vifor Pharma  

Thursday, 22 October 2015, ↓ directly to download

Soho Flordis International (SFI), through its Swiss subsidiary Ginsana SA, will acquire leading UK manufacturer and supplier of traditional herbal treatments Potters, from Vifor Pharma, a company of the Galenica Group.

Potters, based in Wigan, England, has more than 200 years of history as a producer of high quality herbal-based treatments and is the oldest herbal medicine company in the United Kingdom. Its extensive range of well-established products includes treatments for coughs and colds, pain and joint care, gastro-intestinal disorders and women’s health. In addition to this range of products, Potters features brands like Red Kooga®, Seatone®, Calcia™ as well as Equazen™, one of the world’s leading fish oil containing health products.

The Equazen™ brand is backed by robust specific clinical research and in recent years has expanded to deliver brain health solutions to various patient groups. The brand also includes the international product Equazen™ eye-q™. Potters products are sold throughout the UK by leading retailers such as Boots and Holland & Barrett as well as pharmacy and health food outlets.

With subsidiary companies in Europe, Asia and America, the SFI Group draws on more than 70 years of international experience in the high-quality natural health sector. The SFI Group is committed to providing clinically proven natural health solutions to health professionals and consumers worldwide.

Vifor Pharma is a global leader in the treatment of iron deficiency. Vifor Pharma has decided to focus its resources and efforts on maximising and expanding its portfolio of specialty pharmaceuticals as it prepares for life as a stand-alone company.

Nigel Pollard, CEO of SFI, commented: “Potters is a strong and iconic brand in the natural medicine sector. Together with its history of over two centuries, Potters will bring to the SFI Group an excellent team and an extensive portfolio of trusted products. These products and the business platform in the UK and Europe are an excellent fit for SFI as we seek to build our world leading position in the field of clinically-proven natural medicine.”

The transaction is expected to be completed in the fourth quarter of 2015. Financial details of the transaction were not disclosed.

Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world.

For more information about Vifor Pharma and its parent company Galenica, please visit and

Soho Flordis International (SFI), an Australian registered company, is an international provider of clinically proven natural medicines. SFI is committed to identifying and developing leading natural medicines with the best evidence of effectiveness, quality and safety, and marketing them around the world through healthcare professionals with the endorsement of world class opinion leaders.

For more information about SFI, please visit

EquazenTM eye qTM is a dietary supplement with a specific combination of omega-3 and omega-6 fatty acids from natural sources (fish oil and evening primrose oil). EquazenTM eye qTM unique formulation has been tested in clinical trials and showed efficacy in brain function, particularly in children and adolescents with learning disabilities, cognitive & developmental disorders such as dyslexia, dyspraxia, or ADHD-symptoms1,2,3,4.

For more information about EquazenTM eye qTM please visit

  1. M. Johnson, S. Östlund, G. Fransson, B. Kadesjö, C.Gillberg,Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder, J. Atten. Disord. 12 (2008)394–401.
  2. A.J. Richardson, P. Montgomery, The Oxford–Durham study: a randomised, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder, Pediatrics 115(2005)1360–1366.
  3. N. Sinn, J. Bryan, Effect of supplementation with polyunsaturated fatty acids and micronutrients on ADHD-related problems with attention and behavior, J. Dev. Behav. Pediatr. 28(2007)82–91.
  4. N. Sinn, J. Bryan, C. Wilson, Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial, Prostaglandins Leukot. Essent.FattyAcids78 (2008)311–326.

For information about Potters, please visit:


Beatrix Benz

Head of Global Communications & Public Affairs

Vifor Pharma Ltd.

Global Communications
Flughofstrasse 61
P.O. Box
CH-8152 Glattbrugg

+41 58 851 80 00
+41 58 851 80 01

Send link

Send as link